Article Information
History
- March 30, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Rossana Elena Chahla1,
- Luis Medina Ruiz2,
- Eugenia Silvana Ortega3,
- Marcelo Fabio Morales4,
- Francisco Barreiro5,
- Alexia George5,
- Cesar Mancilla4,
- Sylvia Paola D’ Amato4,
- Guillermo Barrenechea3,
- Daniel Gustavo Goroso6 and
- Maria de los Angeles Peral de Bruno*,3
- 1Head SI.PRO.SA (Province Health System), Ministry of Health, Tucumán, Argentina
- 2President of the Medical Executive Secretary, SI.PRO.SA Tucumán, Argentina
- 3Health Research Institute, Ministry of Health, SI.PRO.SA, Tucumán, Argentina
- 4Clinical Hospital “Angel C. Padilla”, Tucumán, Argentina
- 5Medical Center Emergence, Tucumán, Argentina
- 6Research and Technology Center, Mogi das Cruzes University, Brazil., Human Motor Skill Analysis Laboratory, National University of Tucumán, Tucumán, Argentina
- ↵*Corresponding author:
Maria Peral de Bruno, MSc., Ph.D., Health Research Institute, Ministry of Health., Virgen de la Merced 196., (4000) San Miguel de Tucumán, Tucumán, Argentina., E-mail: mperal0150{at}gmail.com, Pronouns: She, her, hers.
Posted March 30, 2021.
A RANDOMIZED TRIAL - INTENSIVE TREATMENT BASED IN IVERMECTIN AND IOTA-CARRAGEENAN AS PRE-EXPOSURE PROPHYLAXIS FOR COVID- 19 IN HEALTHCARE AGENTS
